Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial.

ABSTRACT:

Background

Oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) is a biomarker of increased risk for major adverse cardiovascular events (MACE) in community cohorts, but its role in patients with stable coronary heart disease (CHD) is unknown.

Objectives

This study sought to examine the relationship between these oxidative biomarkers and cardiovascular outcomes in patients with established CHD.

Methods

In a random sample from the TNT (Treating to New Targets) trial, OxPL-apoB levels were measured in 1,503 patients at randomization (after an 8-week run-in period taking atorvastatin 10 mg) and 1 year after being randomized to atorvastatin 10 or 80 mg. We examined the association between baseline levels of OxPL-apoB and MACE, defined as death from CHD, nonfatal myo

SUBMITTER: Byun YS 

PROVIDER: S-EPMC4386070 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature